Skip to main content

Zoetis Inc. company profile

  • ZTS · NYSE
  • Pharmaceuticals
  • S&P 500
$83.82+1.04%Close 13 Nov 2026

About Zoetis Inc.

Zoetis Inc. discovers, develops, manufactures and commercializes animal health medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health products. Its products cover eight core species, including dogs, cats, horses, cattle, swine, poultry, fish and sheep, and span categories such as parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceuticals and animal health diagnostics. Companion animal products represented approximately 70% of revenue in 2025 and livestock products approximately 29%. Customers include veterinarians, pet owners, livestock producers and third-party veterinary distributors. The company sells in more than 100 countries and directly markets its products in approximately 45 countries. The United States accounted for 54% of 2025 revenue.

A summary of the business section of the company's latest annual report, filed 12 Feb 2026.

Company facts

TickerZTS · NYSE
SectorPharmaceuticals
IndustryPharmaceuticals
IndexS&P 500
Fiscal year ends31 December
Reporting currencyUSD
CIK1555280
Latest annual report10-K, filed 12 Feb 2026

Officers and directors

NameRoleShares ownedLatest Form 4
Kristin C. PeckChief Executive Officer · Director493KOption exercise, 19 Feb 2026
Wetteny JosephChief Financial Officer66.9KShares withheld for tax, 19 Feb 2026
Roxanne LaganoExecutive Vice President50.2KOption exercise, 19 Feb 2026
Michael B. McCallisterDirector39.9KGift, 10 Jun 2026
Gregory NordenDirector29.1KGift, 9 Mar 2026
Louise M. ParentDirector26.4KOption exercise, 20 May 2026
Paul M. BisaroDirector25.9KOpen-market purchase, 13 May 2026
Jamie BrannanExecutive Vice President23.4KShares withheld for tax, 19 Feb 2026
Robert PolzerExecutive Vice President21.6KShares withheld for tax, 8 Feb 2025
Willie M. ReedDirector17.9KOption exercise, 19 Feb 2026
Antoinette R. LeatherberryDirector6.8KOption exercise, 19 Feb 2026
Vanessa BroadhurstDirector3.9KOption exercise, 19 Feb 2026
Gavin D.K. HattersleyDirector3.4KOption exercise, 19 Feb 2026
FULLER JULIEExecutive Vice President—Option exercise, 30 Sep 2026
DAMELIO FRANK ADirector—Gift, 7 Aug 2026
Mark StetterDirector—Option exercise, 21 May 2026
Esch KevinExecutive Vice President—Option exercise, 30 Apr 2026
Sarbaugh KeithExecutive Vice President—Option exercise, 31 Mar 2026
Ashton NicholasExecutive Vice President—Shares withheld for tax, 19 Feb 2026
Driscoll RimmaExecutive Vice President—Shares withheld for tax, 19 Feb 2026

Holdings as the latest proxy statement states them, all forms counted; the latest Form 4 line each filed. People appointed since the proxy are listed from their Form 4 filings.

ZTS in the terminal

The business section of every annual report, officers' holdings and trades, and the company's filings as they arrive.